Mark MBA - Volitionrx Chief Officer
| VNRX Stock | USD 0.70 0.09 11.39% |
Insider
Mark MBA is Chief Officer of Volitionrx
| Age | 53 |
| Address | 1489 West Warm Springs Road, Henderson, NV, United States, 89014 |
| Phone | 646 650 1351 |
| Web | https://www.volition.com |
Volitionrx Management Efficiency
The company has return on total asset (ROA) of (1.0082) % which means that it has lost $1.0082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.3006) %, meaning that it created substantial loss on money invested by shareholders. Volitionrx's management efficiency ratios could be used to measure how well Volitionrx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Volitionrx's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 4.75 in 2024, whereas Return On Tangible Assets are likely to drop (1.33) in 2024. At this time, Volitionrx's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 22.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| CCFP DipSportMed | Evolus Inc | 60 | |
| Joshua Riggs | OncoCyte Corp | 41 | |
| Daniel Goldberger | Electrocore LLC | 65 | |
| Iain Strickland | Electrocore LLC | N/A | |
| Lyndal Hesterberg | OncoCyte Corp | N/A | |
| Cavan Redmond | OncoCyte Corp | 58 | |
| Andrew Last | OncoCyte Corp | 59 | |
| Nir Arbel | Evogene | 44 | |
| Thomas MD | Electrocore LLC | 72 | |
| Padma Sundar | OncoCyte Corp | N/A | |
| Jackie Dorsky | Electrocore LLC | N/A | |
| Tony Kalajian | OncoCyte Corp | N/A | |
| Robert Seitz | OncoCyte Corp | 60 | |
| David Erickson | Evolus Inc | N/A | |
| Yaron Eldad | Evogene | 59 | |
| Sara Riordan | OncoCyte Corp | N/A | |
| Dotan Borenstein | Evogene | N/A | |
| Gisela Paulsen | OncoCyte Corp | 58 | |
| Melinda Griffith | OncoCyte Corp | 64 | |
| Ekkehard MD | OncoCyte Corp | N/A | |
| Sandra Beaver | Evolus Inc | 46 | |
Management Performance
| Return On Equity | -7.3 | ||||
| Return On Asset | -1.01 |
Volitionrx Leadership Team
Elected by the shareholders, the Volitionrx's board of directors comprises two types of representatives: Volitionrx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Volitionrx. The board's role is to monitor Volitionrx's management team and ensure that shareholders' interests are well served. Volitionrx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Volitionrx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Faulkes, Executive Chairman | ||
| Salvatore DVM, Chief LLC | ||
| Scott Powell, Executive Relations | ||
| Gael MBA, Chief Officer | ||
| Gaetan Michel, Chief Officer | ||
| Louise Day, Chief Officer | ||
| Jacob MBA, Chief Officer | ||
| Mark MBA, Chief Officer | ||
| Cameron MBA, Group Founder | ||
| Terig Hughes, Group Treasurer | ||
| Thomas Bygott, Sales Director | ||
| Jacob Micallef, Chief Scientific Officer | ||
| Salvatore Butera, Chief LLC | ||
| Andrew MBBS, Chief Officer | ||
| Rodney LLB, Corporate Secretary | ||
| Sharon Ballesteros, U Process | ||
| Nicholas Plummer, Group Counsel |
Volitionrx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Volitionrx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.3 | ||||
| Return On Asset | -1.01 | ||||
| Operating Margin | (17.66) % | ||||
| Current Valuation | 74.04 M | ||||
| Shares Outstanding | 92.66 M | ||||
| Shares Owned By Insiders | 22.80 % | ||||
| Shares Owned By Institutions | 19.10 % | ||||
| Number Of Shares Shorted | 441.92 K | ||||
| Price To Earning | (4.52) X | ||||
| Price To Book | 38.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Volitionrx Stock Analysis
When running Volitionrx's price analysis, check to measure Volitionrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Volitionrx is operating at the current time. Most of Volitionrx's value examination focuses on studying past and present price action to predict the probability of Volitionrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Volitionrx's price. Additionally, you may evaluate how the addition of Volitionrx to your portfolios can decrease your overall portfolio volatility.